Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Protagonist Therapeutics (NASDAQ:PTGX) has scheduled a conference call and webcast for Monday, June 30th at 4:30 pm ET to announce its oral obesity development candidate. The presentation will include details about in vitro and pre-clinical proof-of-concept study results.
Investors can access the call through US dial-in (1-877-407-0752) or international dial-in (1-201-389-0912) using Conference ID 13754335. A webcast replay will be available on the company's Investor Relations webpage after the event.
Protagonist Therapeutics (NASDAQ:PTGX) ha programmato una conference call e una webcast per luned矛 30 giugno alle 16:30 ET per annunciare il suo candidato per lo sviluppo orale contro l'obesit脿. La presentazione includer脿 dettagli sui risultati degli studi di prova di concetto in vitro e pre-clinici.
Gli investitori possono partecipare alla chiamata tramite numero US (1-877-407-0752) o numero internazionale (1-201-389-0912) utilizzando l'ID conferenza 13754335. Una registrazione della webcast sar脿 disponibile sulla pagina Investor Relations della societ脿 dopo l'evento.
Protagonist Therapeutics (NASDAQ:PTGX) ha programado una llamada de conferencia y una transmisi贸n en vivo para el lunes 30 de junio a las 4:30 pm ET para anunciar su candidato para el desarrollo oral contra la obesidad. La presentaci贸n incluir谩 detalles sobre los resultados de estudios de prueba de concepto in vitro y precl铆nicos.
Los inversores pueden acceder a la llamada mediante marcaci贸n en EE.UU. (1-877-407-0752) o internacional (1-201-389-0912) usando el ID de conferencia 13754335. Una repetici贸n en la web estar谩 disponible en la p谩gina de Relaciones con Inversores de la compa帽铆a despu茅s del evento.
Protagonist Therapeutics (NASDAQ:PTGX)电� 6鞗� 30鞚� 鞗旍殧鞚� 鞓ろ泟 4鞁� 30攵� ET鞐� 甑憪 牍勲 旃橂 頉勲炒氍检 氚滍憸毳� 鞙勴暅 旎嵓霟办姢 旖� 氚� 鞗轨簮鞀ろ姼毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 氚滍憸鞐惖鐢 鞁滍棙甏� 雮� 氚� 鞝勳瀯靸� 臧滊厫 歃濍獏 鞐瓣惮 瓴瓣臣鞐� 雽�頃� 靹鸽秬 鞝曤炒臧� 韽暔霅╇媹雼�.
韴瀽鞛愲摛鞚� 氙戈淡 雮� 鞝勴檾(1-877-407-0752) 霕惖鐢 甑牅 鞝勴檾(1-201-389-0912)毳� 韱淀暣 旎嵓霟办姢 ID 13754335毳� 靷毄頃橃棳 旖滌棎 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 鞚措菠韸� 頉� 須岇偓 韴瀽鞛� 甏�瓿� 鞗鬼帢鞚挫鞐愳劀 鞗轨簮鞀ろ姼 鞛儩鞚� 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Protagonist Therapeutics (NASDAQ:PTGX) a programm茅 une conf茅rence t茅l茅phonique et une webdiffusion pour le lundi 30 juin 脿 16h30 ET afin d鈥檃nnoncer son candidat au d茅veloppement oral contre l鈥檕b茅sit茅. La pr茅sentation comprendra des d茅tails sur les r茅sultats des 茅tudes de preuve de concept in vitro et pr茅cliniques.
Les investisseurs peuvent acc茅der 脿 l鈥檃ppel via le num茅ro am茅ricain (1-877-407-0752) ou international (1-201-389-0912) en utilisant l鈥橧D de conf茅rence 13754335. Une rediffusion en webdiffusion sera disponible sur la page Relations Investisseurs de la soci茅t茅 apr猫s l鈥櫭﹙茅nement.
Protagonist Therapeutics (NASDAQ:PTGX) hat eine Telefonkonferenz und Webcast f眉r Montag, den 30. Juni um 16:30 Uhr ET angesetzt, um seinen oralen Entwicklungskandidaten gegen Adipositas vorzustellen. Die Pr盲sentation wird Details zu den in vitro- und pr盲klinischen Proof-of-Concept-Studienergebnissen enthalten.
Investoren k枚nnen 眉ber die US-Einwahlnummer (1-877-407-0752) oder die internationale Einwahlnummer (1-201-389-0912) mit der Konferenz-ID 13754335 an dem Anruf teilnehmen. Eine Aufzeichnung des Webcasts wird nach der Veranstaltung auf der Investor-Relations-Webseite des Unternehmens verf眉gbar sein.
- None.
- None.
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below
NEWARK, CA / / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results.
Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are:
US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13754335
The webcast link for the event can be found here:
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to J&J Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at .
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
+1 833 500 0061 ext 1
[email protected]
SOURCE: Protagonist Therapeutics
View the original on ACCESS Newswire
FAQ
When is Protagonist Therapeutics (PTGX) hosting its conference call about the obesity drug candidate?
How can investors access Protagonist Therapeutics' obesity drug candidate announcement?
What will Protagonist Therapeutics (PTGX) discuss in their upcoming conference call?
Where can I find the replay of Protagonist Therapeutics' obesity drug announcement?
